View Older Stories View More Recent Stories

Jan 11, 2025 11:00AM Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Dec 20, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conference
Dec 17, 2024 08:33AM Gilead Sciences (GILD) Granted FDA Breakthrough Therapy Designation to Trodelvy
Dec 17, 2024 08:30AM U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
Dec 17, 2024 07:02AM Gilead Sciences (GILD) and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Dec 17, 2024 07:00AM Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
Dec 12, 2024 05:30PM Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
Dec 3, 2024 07:00AM Gilead Sciences (GILD) and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Dec 3, 2024 07:00AM Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Nov 27, 2024 05:01PM Gilead Sciences (GILD) Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov 27, 2024 05:00PM Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Nov 15, 2024 11:01AM Gilead Sciences (GILD) Reports Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 15, 2024 11:00AM Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Nov 13, 2024 06:46AM Gilead Sciences (GILD) Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention
Nov 13, 2024 06:45AM Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Nov 12, 2024 05:30AM Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
Nov 8, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Engagements
Nov 7, 2024 08:30AM Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Oct 22, 2024 09:00AM Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
Oct 21, 2024 05:59AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 21, 2024 05:58AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 19, 2024 05:09PM Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Wee
Oct 9, 2024 04:05PM Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
Oct 9, 2024 08:35AM Gilead Sciences (GILD) to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek
Oct 9, 2024 08:30AM Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
Oct 7, 2024 11:00AM Gilead Sciences (GILD) Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Oct 7, 2024 11:00AM Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
Oct 2, 2024 08:32AM Gilead Sciences (GILD) Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countri
Oct 2, 2024 08:30AM Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Sep 12, 2024 08:30AM Gilead's (GILD) Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada
Sep 12, 2024 08:30AM Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Sep 10, 2024 08:02AM Gilead Sciences (GILD) and Genesis Therapeutics Enter Strategic Collaboration to Discover and Develop Novel Therapies
Sep 10, 2024 08:00AM Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Sep 5, 2024 08:07AM Gilead Sciences (GILD) to Present New Trodelvy Data at the IASLC 2024 World Conference on Lung Cancer
Sep 5, 2024 08:00AM Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
Aug 21, 2024 04:05PM Gilead Sciences to Present at Upcoming Investor Conferences
Aug 14, 2024 01:59PM Gilead Sciences' (GILD) Livdelzi Granted Accelerated FDA Approval for Primary Biliary Cholangitis
Aug 14, 2024 01:59PM Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
Jul 25, 2024 04:05PM Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Jul 24, 2024 04:30AM Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
Jul 17, 2024 08:50AM Gilead Sciences (GILD) Announces Upcoming Departure of Chief Medical Officer
Jul 17, 2024 08:50AM Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
Jun 20, 2024 08:51AM Gilead Sciences (GILD) Reports Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada for HIV Prevention
Jun 20, 2024 08:51AM Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
Jun 20, 2024 08:45AM Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
Jun 2, 2024 08:00AM Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Jun 1, 2024 08:00AM Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
May 22, 2024 08:30AM Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
May 9, 2024 04:08PM Kite (GILD) and Arcellx (ACLX) Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024 04:05PM Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
View More Recent Stories View Older Stories